Ricardo L. Dominguez

Ricardo L. Dominguez

Auto-generated profile, based on publicly available information

Ricardo L. Dominguez

Western Honduras Gastric Cancer Program, Ministry of Health, Santa Rosa de Copan, Honduras

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2012 in Cancer Causes & Control
Verified
Journal Article
Open access
PDF file
RDRicardo L. Dominguez
Ricardo L. Dominguez
SCSeth D. Crockett
Seth D. Crockett
JLJennifer L. Lund
Jennifer L. Lund
LSLia P. Suazo
Lia P. Suazo
PHParis Heidt
Paris Heidt
DMDouglas Morgan
Douglas Morgan
Cancer epidemiology is challenging in developing nations, in the absence of reliable pathology-based cancer registries. Clinical experience suggests that the incidence of gastric cancer is high in Honduras, in contrast to the limited available national statistics at the time of study initiation (IARC GLOBOCAN 2002: males 15.2, females 10.8). We estimate the incidence of gastric cancer for Honduras using an endoscopy registry as a complimentary resource.

21 November 2014 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Open access
PDF file
JCJuan E. Corral
Juan E. Corral
JHJuan J. Delgado Hurtado
Juan J. Delgado Hurtado
RDRicardo L. Domínguez
Ricardo L. Domínguez
MCMarisabel Valdez de Cuéllar
Marisabel Valdez de Cuéllar
CCCarlos Balmore Cruz
Carlos Balmore Cruz
DMDouglas Morgan
Douglas Morgan
The aims of this study were to delineate the epidemiology of gastric adenocarcinoma in Central America and contrast it with Hispanic-Latino populations in the USA.

1 July 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
RDRicardo L. Dominguez
Ricardo L. Dominguez
EMEleazar E. Montalvan-Sanchez
Eleazar E. Montalvan-Sanchez
DNDalton A. Norwood
Dalton A. Norwood
ARAida Rodriguez-Murillo
Aida Rodriguez-Murillo
LDLucia Dominguez
Lucia Dominguez
DMDouglas Morgan
Douglas Morgan
Background: Two-thirds of global cancers occur in low/middle income countries (LMIC). Northern Central America is the largest LMIC region in the Western Hemisphere and lack cancer registries to guide cancer control. We conducted a gastric cancer survival study in rural Western Honduras, characterized as having among the highest gastric cancer incidence rates in Latin America. Methods: The cohort of incident gastric cancer diagnosed between 2002 and 2015 was studied with active follow-up with household visits. The regional gastric cancer registry was primary for case identification, with completeness examination with hospital data and national death certificates. Cox regression models were used for survival calculations. Results: Survival follow-up was achieved in 741/774 patients (95.7%). Household interviews were conducted in 74.1% (n = 549); 65.7% were male, median age at diagnosis was 64 years, 24.5% were <55 years; 43.9% of tumors had pyloric obstruction; 45.2%, 43.2%, and 7.3% of histology was intestinal, diffuse, and mixed, respectively. A total of 24.7% patients received treatment. The 5-year survival rates were 9.9% for both males and females, 7.7% for age <45, and 7.9% for diffuse gastric cancer. Median survival time was 4.8 months [95% confidence interval (CI), 4.2–5.6]. In the final Cox regression model including age, sex, Lauren subtype, and poverty index, only treatment was significantly associated with survival (hazard ratio = 2.43, 95% CI, 1.8–3.2). Conclusions: Markedly low gastric cancer 5-year survival rates are observed in rural Central America. The majority of patients present with advanced disease and a minority have access to therapy. Impact: The findings have implications for cancer control in the Central America LMICs and for US Latino populations. See related commentary by Riquelme and Abnet, p. 1550

1 August 2018
Verified
Conference Paper
Closed access
RDRicardo Dominguez
Ricardo Dominguez
JSJavier Solano
Javier Solano
AJAndres Jacome
Andres Jacome
This paper introduces a methodology to size the fuel cell (FC) and ultracapacitor (UC) in a FC-UC hybrid electric vehicle (FC-UC HEV). The inputs of the methodology are the FC and UC datasheets and power profiles to drive the vehicle. The methodology considers two different energy management strategies (EMS) to define the power distribution between the FC and the UC. The methodology is performed to compare FC and UC sizes obtained with an optimal EMS based on dynamical programming and with a rule-based EMS based on fuzzy logic.

16 August 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
EMEleazar E. Montalvan-Sanchez
Eleazar E. Montalvan-Sanchez
JHJessica Hernandez-Marrero
Jessica Hernandez-Marrero
DNDalton A. Norwood
Dalton A. Norwood
MGMaria Gonzalez-Pons
Maria Gonzalez-Pons
RDRicardo L. Dominguez
Ricardo L. Dominguez
DMDouglas Morgan
Douglas Morgan
Gastric adenocarcinoma (GAC) is the fourth leading global cause of cancer mortality and leading infection-associated cancer. High-incidence regions of GAC include Latin America and Eastern Asia. Immigrants from high-incidence regions maintain their GAC risk. GAC is a major U.S. cancer disparity, and its incidence rates are 2 to 10 times higher in non-White populations. Emerging guidelines recommend 3-year surveillance endoscopy for patients with high-risk gastric premalignant conditions (GPMC). Clinical trials of GPMC chemoprevention agents are lacking. We conducted a NCI Division of Cancer Prevention–funded, phase II placebo-controlled chemoprevention trial in patients with GPMCs (atrophic gastritis and intestinal metaplasia) with a highly bioavailable preparation of curcuminoids (Meriva). The trial sites in Puerto Rico and rural Honduras had important characteristics: (i) representative Caribbean and Mesoamerican populations, linked to large U.S. immigrant populations; (ii) high prevalence of Helicobacter pylori infection and GPMCs; (iii) the absence of turmeric and curcuminoids in local diets; and (iv) proven bidirectional collaboration with U.S. academic institutions. H. pylori–negative patients with GPMCs were randomized to the study drug (500 mg po bid) or placebo for 180 days (NCT02782949), with primary outcomes based upon histologic parameters. Principal study challenges included (i) an international regulatory environment; (ii) research infrastructure strengthening, particularly in Central America; (iii) participant recruitment in Honduras, wherein only 10% to 15% are H. pylori negative; (iv) the COVID-19 pandemic; and (v) natural disasters (three hurricanes). There were no losses to follow-up related to the pandemic or natural disasters. In conclusion, the south–south partnership provides a model for chemoprevention and translational studies in Latino populations with prevalent cancers, such as GAC.

10 July 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
LCLisseth Ruiz de Campos
Lisseth Ruiz de Campos
MCMarisabel Valdez de Cuellar
Marisabel Valdez de Cuellar
DNDalton A. Norwood
Dalton A. Norwood
TCTiffany Y. Carrasco
Tiffany Y. Carrasco
EMEleazar E. Montalvan-Sanchez
Eleazar E. Montalvan-Sanchez
DMDouglas Morgan
Douglas Morgan
Background: Gastric adenocarcinoma is the fourth leading cause of global cancer mortality and leading infection-associated cancer. Gastric cancer has significant geographic variability, with a high incidence in East Asia and mountainous regions of Latin America. In the United States, gastric cancer represents a marked disparity with incidence rates that are two to three times higher in Hispanics compared to non-Hispanic Whites. Methods: We conducted a national retrospective study of incident gastric cancer in El Salvador from to 2000 to 2014 to estimate the age-standardized incidence rate (ASIR) by using a combination of pathology and endoscopy databases. A unique multisectorial coalition was formed between the Ministry of Health (MINSAL) and ES Gastroenterology Society (AGEDES), representing public hospitals (n = 5), governmental employee hospitals (ISSS, n = 5), and private facilities (n = 6), accounting for >95% of national endoscopy capacity. HER2 and EBV tumor status was ascertained in a representative sample during 2014 to 2016. Results: A total of 10,039 unique cases of gastric cancer were identified, 45.5% female, and mean age of 65. 21% and 9.4% were <55 and <45 years old, respectively. ASIRs (M, F) were 18.9 (95% CI, 14.4–20.7) and 12.2 per 100,000 persons (95% CI, 10.9–13.5), respectively, in the period 2010 to 2014 with all centers operational. Intestinal gastric cancer was 2.8 times more common than diffuse gastric cancer; 23.2% had partial or complete pyloric obstruction. The HER2 2+/3+ status was 16.7% and EBV-encoded RNA positivity was 10.2%. Conclusions: A high incidence of gastric cancer was confirmed in El Salvador and nearly half of the patients were female. Impact: The findings have implications for cancer control in the Central America LMICs and for US Latino populations. See related commentary by Riquelme and Abnet, p. 1550